ArticleiScience2026
Optimizing in-context exemplars for a generalist vision-language model to support region of interest selection in ovarian tumor grossing.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathological gross examination guides tissue sampling in heterogeneous ovarian tumors, where mixed components can complicate selection of representative regions. We evaluated whether a generalist large vision-language model can support gross image analysis through pathology-informed in-context exemplars. Using Qwen-2.5-Vision-Language-72B, we developed single-component exemplar optimization and histology-guided exemplar optimization to promote component-aware reasoning and region-level risk flagging. In a single-institution retrospective cohort, the optimized eight-shot strategy achieved 89.8% image-level accuracy on mixed ovarian tumors and improved region-level demarcation relevant to sampling. In borderline tumors with microinvasion or microinvasive carcinoma, model-identified regions encompassed pathologist-defined sampling areas, supporting risk flagging rather than stand-alone diagnosis. In rare malignant tumors (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.